PONVORY Drug Patent Profile

When do Ponvory patents expire, and what generic alternatives are available?

Ponvory is a drug marketed by Vanda Pharms Inc and is included in one NDA. There are five patents protecting this drug.

This drug has one hundred and fifty-six patent family members in forty-two countries.

The generic ingredient in PONVORY is ponesimod. Two suppliers are listed for this compound. Additional details are available on the ponesimod profile page.

DrugPatentWatch^® Generic Entry Outlook for Ponvory

Ponvory was eligible for patent challenges on March 18, 2025.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 16, 2029. This may change due to patent challenges or generic licensing.

There have been six patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for PONVORY

International Patents:	156
US Patents:	5
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	46
Clinical Trials:	1
Drug Prices:	Drug price information for PONVORY
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for PONVORY
What excipients (inactive ingredients) are in PONVORY?	PONVORY excipients list
DailyMed Link:	PONVORY at DailyMed

See drug prices for PONVORY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for PONVORY

NDA:

213498

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for PONVORY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Janssen Pharmaceutica N.V., Belgium	Phase 1

See all PONVORY clinical trials

Pharmacology for PONVORY

Drug Class	Sphingosine 1-phosphate Receptor Modulator
Mechanism of Action	Sphingosine 1-Phosphate Receptor Modulators

US Patents and Regulatory Information for PONVORY

PONVORY is protected by five US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-007	Mar 18, 2021		RX	Yes	No			Y	Y
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-006	Mar 18, 2021		RX	Yes	No			Y	Y
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-009	Mar 18, 2021		RX	Yes	No

Expired US Patents for PONVORY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-002	Mar 18, 2021
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-007	Mar 18, 2021
Vanda Pharms Inc	PONVORY	ponesimod	TABLET;ORAL	213498-005	Mar 18, 2021

EU/EMA Drug Approvals for PONVORY

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Janssen-Cilag International N.V.	Ponvory	ponesimod	EMEA/H/C/005163Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Authorised	no	no	no	2021-05-19

International Patents for PONVORY

See the table below for patents covering PONVORY around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015359306
Australia	2015359346
Australia	2020202684

Supplementary Protection Certificates for PONVORY

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3256125	301174	Netherlands		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT
3256125	PA2022505	Lithuania		PRODUCT NAME: PONEZIMODAS; REGISTRATION NO/DATE: EU/1/21/1550 20210519
3256125	2022C/515	Belgium		DETAILS ASSIGNMENT: CHANGE OF OWNER(S), ASSIGNMENT

PONVORY (ponesimod) Market Dynamics and Financial Trajectory: Sales Trend, Growth Drivers, Pricing Pressure, and Patent/Competition Risk

Last updated: July 27, 2026

PONVORY (ponesimod) is one of the key S1P receptor modulator franchise assets in multiple sclerosis (MS). Its financial trajectory is tied to (1) uptake versus competing S1P modulators, (2) payer coverage and step-edit barriers, (3) persistence and discontinuation rates relative to oral peers, and (4) competitive entry timing from generics and other branded MS therapies. The practical market question for 2026 is whether PONVORY maintains net sales growth through continued formulary access and durable patient retention, or faces share loss as payers tighten controls on high-cost oral MS drugs and as alternate mechanisms/combination regimens gain share.

---

How much revenue does PONVORY generate and how is sales trending?

Fast answer: PONVORY’s revenue trend follows a typical late-launch MS pattern: ramp post-approval, scaling with formulary penetration and prescriber adoption, then deceleration if payer restrictions tighten or if competitors broaden coverage.

Key financial indicators that move PONVORY net sales

• Formulary access and tier placement (commercial and Medicare Part D)
• Prior authorization and step therapy rates
• High persistence vs. class discontinuation (S1P drugs share similar discontinuation risks)
• Dose adherence and real-world discontinuation after early side effects (macular edema, lymphopenia monitoring burden)
• Switching behavior among S1P modulators (patients often switch within class rather than switch to a different mechanism)

What to track in company filings and payer datasets

• Net sales by quarter and year in the owning company segment reporting
• Gross-to-net effects: rebates, copay support, and government pricing adjustments
• Script volume vs. average selling price changes
• Treatment-naïve vs. switcher mix (switchers usually adopt faster if formulary is restrictive for naïve patients)

---

What market share is PONVORY taking in relapsing multiple sclerosis and how does it compare with competitors?

Fast answer: PONVORY competes in a crowded “oral DMT” MS market dominated by S1P receptor modulators and is evaluated by prescribers and payers on convenience, safety monitoring complexity, and outcomes evidence.

Competitive set for PONVORY

• Other oral S1P modulators: fingolimod (and newer derivatives in the class where applicable), siponimod, fingolimod-related products (depending on country), ozanimod, and similar mechanism options
• High-efficacy oral and infusion MS options that pressure tiering and step-edit policies
• Payers also consider total cost of therapy including monitoring and managed adverse events

Positioning levers for PONVORY vs. oral MS peers

• Oral daily administration improves convenience vs. infusion therapies
• S1P class familiarity drives uptake, since clinicians and payers understand the monitoring framework
• Differentiation depends on safety and switching economics, not just mechanism

---

What payer dynamics affect PONVORY profitability and net price realization?

Fast answer: PONVORY’s profitability is primarily driven by gross-to-net and managed access. MS specialty drugs are rebate-heavy and subject to aggressive formulary negotiations.

Commercial payer dynamics that typically impact S1P modulators

• Rebate contracting based on formulary tier and preferred drug lists
• PA criteria that reduce new starts and raise switching friction
• Utilization management tied to clinical criteria (relapsing MS activity, prior DMT history)
• Specialty pharmacy channel strategy influencing patient access and adherence

Government pricing impact

• Medicare and Medicaid create additional pressure through statutory rebates and price erosion
• Changes in utilization patterns often show up as higher rebates even if gross sales are stable

---

What are the main growth drivers for PONVORY net sales?

Fast answer: Growth tends to be driven by formulary wins, patient persistence, and share capture from less preferred DMTs.

Demand-side growth drivers

• Expanded access through commercial formulary placement
• Continued new patient starts as neurologists adopt additional S1P options
• Switching volumes from other DMTs where safety tolerability and monitoring burden are decisive

Operational growth drivers

• Patient support programs that improve adherence and persistence
• Monitoring infrastructure (baseline exams, ongoing labs, and management pathways)
• Specialty pharmacy effectiveness in mitigating therapy interruptions

---

What risks threaten PONVORY financial performance?

Fast answer: The largest threats are payer-driven utilization management, discontinuation that reduces persistence, adverse-event-driven interruptions, and competitive share loss.

Category risks for S1P MS therapies

• Class-level discontinuation due to lymphocyte changes, macular edema risk, and infection concerns
• Monitoring burden cost and operational drag can worsen real-world persistence
• Tighter payer edits reduce net starts and increase time-to-therapy

Share loss risks

• Competitors with broader coverage or better negotiated rebate terms
• Competitors with superior access pathways (lower PA friction or preferred access)

---

When does PONVORY lose exclusivity and what is the generic/biosimilar risk profile?

Fast answer: For oral small-molecule MS drugs like PONVORY, exclusivity risk is typically driven by the intersection of patent expiry, pediatric exclusivity (if any), and any unexpired supplementary protection such as method-of-use and formulation patents. Generic entry timelines depend on Orange Book listings and the ability to carve out protected claims via Paragraph IV (for ANDA).

How generic entry would likely happen

• ANDAs for ponesimod tablets or equivalent formulations
• Paragraph IV certifications tied to Orange Book-listed patents
• Potential litigation triggers that can delay launch via 30-month stay and settlements

What matters most for decision-making

• Count of Orange Book patents with unexpired status by claim type (composition, method of use, formulation)
• Whether any method-of-use patents cover specific dosing or patient subpopulations
• Whether settlements include non-claim terms (launch limits) or market allocation

---

What patents protect PONVORY and how strong is the patent estate?

Fast answer: Patent strength in MS S1P drugs is usually distributed across composition of matter, formulation, and method-of-use. The “strongest” estate is the one with surviving claim coverage that is hard to design around for an ANDA route.

Patent estate components to assess for PONVORY

• Drug substance (composition of matter)
• Formulation (tablet composition, excipients, stability)
• Methods of treatment (relapsing MS treatment, patient selection)
• Manufacturing methods (process controls and impurity profiles)

Litigation posture and settlement history (what to look for)

• Whether generic filers challenged core composition patents or only formulation/method patents
• Whether disputes settled early (fewer remaining barriers) or late (stronger claim survival)

(Note: No Orange Book patent list or expiry dates are provided in the prompt; without them, a complete expiration-by-patent map cannot be generated.)

---

What Orange Book status is PONVORY in and which patents are listed?

Fast answer: Orange Book status determines timing for ANDA approvals. A full listing is required to answer definitively, including listed active ingredients, dosage forms, and patent numbers.

(No Orange Book listing data is provided in the prompt; a complete, accurate Orange Book table cannot be produced.)

---

Has PONVORY faced Paragraph IV challenges or ANDA litigation that affects future revenue?

Fast answer: The impact of Paragraph IV depends on the number of challenges, who filed, which patents were certified, and whether settlements restrict launch.

(No Paragraph IV filings, court dockets, or settlement terms are provided in the prompt; an accurate litigation and timeline summary cannot be produced.)

---

How does PONVORY compare with ozanimod, siponimod, and other MS S1P drugs on market economics?

Fast answer: Comparison is mainly payer-driven. S1P drugs trade off on formulary access, PA criteria, and rebate economics rather than wholesale wholesale price.

Practical differentiators that influence payer and clinician behavior

• Safety monitoring intensity and downstream cost management
• Switching convenience for patients moving from other DMTs
• Trial evidence strength translated into guideline support and coverage decisions
• Patient support services that reduce dropout and switching churn

Typical competitive pattern

• If PONVORY is preferred on a subset of payers, share can expand quickly even without being the cheapest
• If it is non-preferred, net sales often track slower growth and rely on clinician persistence in the face of PA delays

---

What formulation or dosing patents could affect generic design-around risk for PONVORY?

Fast answer: If formulation patents are core to Orange Book coverage, generics must replicate composition in ways that preserve noninfringement. Even when composition of matter expires, formulation and method-of-use patents can delay launch.

(No specific formulation patents or claim scope are provided in the prompt; a claim-level analysis cannot be completed.)

---

What market and financial milestones should investors monitor for PONVORY through 2030?

Fast answer: The key milestones are coverage expansion, persistence durability, and patent/liability events that affect generic threats.

Milestones by timeline category

• Quarterly: new prescriptions, persistence trends, gross-to-net stabilization
• Annual: formulary position changes, government pricing impacts, competitor rebate shifts
• Event-driven: patent expiration windows, ANDA approvals, court rulings, and settlement-triggered launch delays

---

Key Takeaways

• PONVORY competes in the crowded oral S1P MS space where payer access and net price realization drive financial outcomes as much as clinical differentiation.
• Near-term financial trajectory is most sensitive to formulary placement, prior authorization friction, and patient persistence.
• Exclusivity and generic entry risk must be evaluated using Orange Book patent-by-patent expiry and any Paragraph IV litigation, which are not included in the prompt and therefore cannot be mapped accurately here.
• For decision-making, the highest-value monitoring items are gross-to-net trends, treatment mix, and early discontinuation rates relative to oral competitors.

---

FAQs

1) What parts of net sales most commonly decline for S1P MS drugs like PONVORY?

Rebates, copay support leakage, and government pricing adjustments usually drive gross-to-net deterioration even when scripts rise.

2) How do prior authorization policies affect PONVORY patient starts?

Stricter PA criteria reduce new starts and increase time on waitlists, often shifting utilization toward more preferred DMTs.

3) What real-world factors most influence persistence for oral MS therapies?

Adverse-event monitoring burden, infection risk management, and tolerability drive discontinuations and dose interruptions.

4) What patent categories typically delay generic entry for oral small-molecule MS drugs?

Formulation and method-of-use patents can delay ANDA launches even after composition-of-matter expiry.

5) What competitive event most changes payer coverage quickly in MS?

A rapid net-price renegotiation, preferred formulary placement, or aggressive contracting by a dominant oral peer can shift market share.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. (Accessed 2026-07-27).
2. FDA. Drug Trials Snapshots. U.S. Food and Drug Administration. (Accessed 2026-07-27).

DrugChatter Q&A for PONVORY

Ponvory pharmaceuticals company profile?
Ponvory market share sales revenue 2025 2026 janssen?
What are the side effects of Ponvory?